Letermovir Pill

Phase 2Small molecule

TThe First Affiliated Hospital of Soochow University

Letermovir Pill is one of 7 small molecule programs targeting Transplant Recipient. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Transplant RecipientRecruiting

Transplant RecipientPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Transplant Recipient

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 3

Adrucil

EElorac, Inc.

Phase 2

1 4

Sorilux

LEO Pharma

Phase 2

1 5

Letermovir Pill

TThe First Affiliated Hospital of Soochow University

Phase 2

1 6

Myfortic

Novartis

Preclinical

1 7

Bradykinin

VVanderbilt University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Prophylaxis

NCT06812598

Clinical

Trials by Indication[1]

Prophylaxis1 trial

Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

Recruiting·TThe First Affiliated Hospital of Soochow University·N/A·NCT06812598·330 enrolled

CMV Infection1 trial

Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06021210·80 enrolled

Transplant Recipient1 trial

Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients

Recruiting·UUniversity Medical Centre Ljubljana·Phase 2·NCT05432778·90 enrolled

Cytomegalovirus (CMV) Infection1 trial

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04017962·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Letermovir Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letermovir Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letermovir Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Soochow University

Letermovir Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prophylaxis1 trial

CMV Infection1 trial

Transplant Recipient1 trial

Cytomegalovirus (CMV) Infection1 trial

References

Drug Info

Quick Facts

Related News